+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CRISPR Technology: Global Markets

  • PDF Icon

    Report

  • 131 Pages
  • January 2023
  • Region: Global
  • BCC Research
  • ID: 5027805

The current report provides detailed exposure to the CRISPR technology market. This report highlights the current and future market potential of CRISPR technology, along with a detailed analysis of the drivers, restraints, and challenges in the market. The report also covers market projections for 2027, as well as the competitive environment and regulatory scenario. The report details the market share of CRISPR technology on applications and end users. The market is segmented into Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, and Contract Research Organizations (CROs) based on end users. The market is categorized as Drug Development, Agriculture, Diagnostics, Clinical therapy, and Others based on Application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also discusses the impact of the COVID-19 pandemic on this market.

By geography, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year, and forecast for 2027.

Report Includes

  • 17 data tables and 37 additional tables
  • An up-to-date overview and analysis of the global market for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology
  • Analyses of the global market trends, with historic revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the market potential for CRISPR technology, industry growth drivers, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size and revenue forecast for the global CRISPR technology market in USD million terms, and corresponding market share analysis by application, end user, and region
  • Discussion of the major market dynamics, key shifts and regulations, industry specific challenges, and macroeconomic factors affecting the demand for CRISPR technology market over the coming years (2022-2027)
  • Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances, or other advantages
  • A look at the recent technical breakthrough on the use of CRISPR-Cas9 genome editing technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
  • Comparative study on CRISPR with TALE and ZFN nuclease as a gene editing tool and discussion on its higher adaptability over other nucleases
  • Review of the patent filings and research publications for innovations in the CRISPR-Cas9 genome editing technology
  • Insight into recent industry structure for CRISPR-Cas9 genome editing technology, competitive environment, clinical trials, ongoing research activities, and the COVID-19 impact on the marketplace
  • Company profiles of major players within the industry, including CRISPR Therapeutics AG, GenScript, Lonza Group Ltd, PerkinElmer and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 Intended Audience
1.4 Scope of Report
1.5 What's New in this Report?
1.6 Information Sources
1.7 Methodology
1.8 Geographic Breakdown
1.9 Analyst's Credentials
1.10 Custom Research
1.11 Related Research Reports

Chapter 2 Summary and Highlights
2.1 Highlights of the Market for Crispr Technology

Chapter 3 Market Overview
3.1 Crispr: Genetic Editing
3.2 Components of Crispr-Cas Systems
3.2.1 Sgrna
3.2.2 Cas9 Nucleases
3.3 How Crispr-Cas Works?
3.4 Advantage of the Crispr-Cas9 System
3.5 Popularity of Crispr Genome Editing
3.6 Pros of Genetic Editing
3.7 Crispr Development Phases
3.7.1 Discovery of Crispr
3.7.2 Discovery of Cas9 and Pam
3.7.3 Hypothesis: Adaptive Immunity
3.7.4 Adaptive Immunity
3.7.5 Spacer Sequences: Grnas
3.7.6 Crispr Acts on Dna Targets
3.7.7 Cas9 Cleaves Target Dna
3.7.8 Tracrrna for Cas9 Systems
3.7.9 Crispr Systems in Other Species
3.7.10 Cas9-Mediated Cleavage
3.7.11 Crispr-Cas9: Genome Editing
3.8 Market Potential
3.9 Regulatory Framework
3.9.1 U.S. Regulation and Oversight
3.9.2 Nih Guidelines
3.9.3 U.S. Fda
3.9.4 Regulatory Issues
3.9.5 Regulations of Human Germline Edits
3.9.6 Global Regulations
3.10 Porter's Five Forces Analysis of the Market for Crispr Technology
3.10.1 Bargaining Power of Suppliers: Low
3.10.2 Bargaining Power of Buyers: Moderate
3.10.3 the Threat of Substitutes: Moderate
3.10.4 the Threat of New Entrants: Moderate
3.10.5 the Intensity of Competitive Rivalry: Low
3.11 Scientific Publications
3.12 Patent Analysis
3.12.1 Overview of Crispr Technology Intellectual Property (Ip) and Licensing Structure
3.13 Future of Crispr
3.14 Market Drivers
3.14.1 Crispr Versus Chronic Disease
3.14.2 High Prevalence of Genetic Disorders
3.14.3 Government and Private Funding
3.14.4 Increasing Applications of Crispr
3.15 Market Restraints
3.15.1 Alternative Technologies
3.15.2 Off-Target Activity
3.16 Market Challenges
3.16.1 Patent Issues
3.16.2 Risks Associated With Crispr
3.16.3 R&D
3.16.4 Governmental Policies and Regulations
3.16.5 Bioethical Issues

Chapter 4 Industry Structure
4.1 Commercial Therapeutics
4.2 Correcting Genetic Errors
4.3 Microbes
4.4 Healthier Food

Chapter 5 Impact of Covid-19 on the Market for Crispr Technology
5.1 Overview

Chapter 6 Competitive Landscape
6.1 Overview
6.2 Competitive Scenario
6.3 Beam Therapeutics
6.4 Crispr Therapeutics
6.5 Editas Medicine
6.6 Intellia Therapeutics
6.7 Growth Strategies
6.7.1 Licensing and Agreements
6.7.2 Collaborations With Big Biopharmaceutical Companies
6.7.3 Mergers and Acquisitions

Chapter 7 Global Market for Crispr Technology by End-user
7.1 Market Overview
7.2 Market Share and Forecast
7.3 Biotechnology and Pharmaceutical Companies
7.4 Academics and Government Research Institutes
7.5 Contract Research Organizations

Chapter 8 Global Market for Crispr Technology by Application
8.1 Market Share and Forecast
8.2 Drug Development
8.3 Agriculture
8.4 Diagnostics
8.4.1 Infectious Diseases
8.4.2 Non-Infectious Diseases
8.5 Clinical Therapy
8.6 Others

Chapter 9 Global Market for Crispr Technology by Region
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 United Kingdom
9.2.3 France
9.2.4 Rest of Europe
9.3 Asia-Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Rest of Asia-Pacific
9.4 Rest of the World

Chapter 10 Company Profiles

  • Caribou Biosciences
  • Crispr Therapeutics AG
  • Danaher Corp.
  • Editas Medicine
  • Genscript
  • Hera Biolabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences Inc.
  • New England Biolabs Inc.
  • Origene Technologies
  • Perkinelmer
  • Precision Biosciences
  • Synthego
  • Thermo Fisher Scientific
  • Toolgen Inc.

List of Tables
Summary Table B: Global Market for CRISPR Technology, by Region, Through 2027
Summary Table A: Global Market for CRISPR Technology, by End User, Through 2027
Table 1: Comparison of Genome Editing Technologies
Table 2: Selected Monogenic Disease Details
Table 3: CRISPR Applications
Table 4: Global Incidence of Cancer, by Cancer Type/Site, 2020
Table 5: Venture Capitalist Funding, by Company in Gene Editing
Table 6: Bioethical Issues and Risks Associated with CRISPR Technology
Table 7: Selected CAR-T/Gene-Editing Collaborations
Table 8: CRISPR Technology: Competitive Scenario
Table 9: CRISPR Technology: Selected Companies
Table 10: Global Market for CRISPR Technology, by End User, Through 2027
Table 11: Collaborations among Biotechnology and Pharmaceutical CRISPR Technology Companies
Table 12: Global Market for CRISPR Technology in Biotechnology and Pharmaceutical End Uses, by Region, Through 2027
Table 13: Companies Licensing CRISPR Technology from Research Institutions
Table 14: Global Market for CRISPR Technology in Academic and Government Research Institute End Uses, by Region, Through 2027
Table 15: Global Market for CRISPR Technology in Contract Research Organization End Uses, by Region, Through 2027
Table 16: Global Market for CRISPR Technology, by Application, Through 2027
Table 17: Global Market for Drug Development Applications of CRISPR Technology, by Region, Through 2027
Table 18: CRISPR: Edited Crops
Table 19: Global Market for Agriculture-Based Applications of CRISPR Technology, by Region, Through 2027
Table 20: Global Market for Diagnostic Applications of CRISPR Technology, by Region, Through 2027
Table 21: Clinical Trial Using CRISPR Technology for Chronic Disease
Table 22: Global Market for Clinical Therapeutic Applications of CRISPR Technology, by Region, Through 2027
Table 23: Global Market for Other Applications of CRISPR Technology, by Region, Through 2027
Table 24: Global Market for CRISPR Technology, by Region, Through 2027
Table 25: European Market for CRISPR Technology, by Country, Through 2027
Table 26: Asia-Pacific Market for CRISPR Technology, by Country, Through 2027
Table 27: Caribou Biosciences: Product Portfolio
Table 28: Caribou Biosciences: Recent Developments, 2021
Table 29: CRISPR Therapeutics AG: Product Portfolio
Table 30: CRISPR Therapeutics AG: Recent Developments, 2021 and 2022
Table 31: Danaher: Product Portfolio
Table 32: Danaher: Recent Developments, 2020 and 2021
Table 33: Editas Medicine: Product Portfolio
Table 34: Editas Medicine: Recent Developments, 2020-2022
Table 35: GenScript: Product Portfolio
Table 36: GenScript: Recent Developments, 2020 and 2021
Table 37: Hera Biolabs: Product Portfolio
Table 38: Hera Biolabs: Recent Developments, 2020 and 2021
Table 39: Intellia Therapeutics Inc.: Product Portfolio
Table 40: Intellia Therapeutics Inc.: Recent Developments, 2020-2022
Table 41: Lonza Group Ltd.: Product Portfolio
Table 42: Lonza Group Ltd.: Recent Developments, 2020 and 2021
Table 43: Mammoth Biosciences Inc.: Recent Developments, 2020-2022
Table 44: New England Biolabs Inc.: Product Portfolio
Table 45: New England Biolabs Inc.: Recent Developments, 2020 and 2021
Table 46: OriGene Technologies: Product Portfolio
Table 47: PerkinElmer: Product Portfolio
Table 48: PerkinElmer: Recent Developments, 2020 and 2021
Table 49: Precision BioSciences: Product Portfolio
Table 50: Precision BioSciences: Recent Developments, 2020-2022
Table 51: Thermo Fisher Scientific Inc.: Product Portfolio
Table 52: Thermo Fisher Scientific Inc.: Recent Developments, 2020-2022

List of Figures
Summary Figure A: Global Market for CRISPR Technology, by End User, 2019-2027
Summary Figure B: Global Market for CRISPR Technology, by Region, 2019-2027
Figure 1: CRISPR Timeline, 2016-2021
Figure 2: Distribution Shares of Scientific Publications on Genome Editing, by Technology, 2018-2021
Figure 3: Distribution of Scientific Publications on Genome Editing, by Year, 2018-2021
Figure 4: Published Patents on CRISPR Technology, 2011-2021
Figure 5: Patent Filings on CRISPR Technology, by Jurisdiction, 2011-2021
Figure 6: Share of Patent Filings on CRISPR Technology, by Applicant, 2011-2021
Figure 7: Global Market Shares of CRISPR Technology, by End User, 2021
Figure 8: Global Market for CRISPR Technology in Biotechnology and Pharmaceutical End Uses, by Region, 2019-2027
Figure 9: Global Market Shares of CRISPR Technology in Biotechnology and Pharmaceutical End Uses, by Region, 2021
Figure 10: Global Market for CRISPR Technology in Academic and Government Research Institute End Uses, by Region, 2019-2027
Figure 11: Global Market Shares of CRISPR Technology in Academic and Government Research Institute End Uses, by Region, 2021
Figure 12: Global Market for CRISPR Technology in Contract Research Organization End Uses, by Region, 2019-2027
Figure 13: Global Market Shares of CRISPR Technology in Contract Research Organization End Uses, by Region, 2021
Figure 14: Global Market Shares of CRISPR Technology, by Application, 2021
Figure 15: CRISPR Technology in Drug Development
Figure 16: CRISPR Technology Usage in Drug Development, by Phase (Commercial)
Figure 17: CRISPR Technology Usage in Drug Development, by Phase (Non-commercial)
Figure 18: Global Market for Drug Development Applications of CRISPR Technology, by Region, 2019-2027
Figure 19: Global Market Shares of Drug Development Applications of CRISPR Technology, by Region, 2021
Figure 20: Global Market for Agriculture-Based Applications of CRISPR Technology, by Region, 2019-2027
Figure 21: Global Market Shares of Agriculture-Based Applications of CRISPR Technology, by Region, 2021
Figure 22: Global Market for Diagnostic Applications of CRISPR Technology, by Region, 2019-2027
Figure 23: Global Market Shares of Diagnostic Applications of CRISPR Technology, by Region, 2021
Figure 24: Global Market for Clinical Therapeutic Applications of CRISPR Technology, by Region, 2019-2027
Figure 25: Global Market Shares of Clinical Therapeutic Applications of CRISPR Technology, by Region, 2021
Figure 26: Global Market for Other Applications of CRISPR Technology, by Region, 2019-2027
Figure 27: Global Market Shares of Other Applications of CRISPR Technology, by Region, 2021
Figure 28: Snapshot of the Global Market for CRISPR Technology
Figure 29: North American Market for CRISPR Technology, 2019-2027
Figure 30: European Market Shares of CRISPR Technology, by Country, 2021
Figure 31: German Market for CRISPR Technology, 2019-2027
Figure 32: U.K. Market for CRISPR Technology, 2019-2027
Figure 33: French Market for CRISPR Technology, 2019-2027
Figure 34: Rest of the European Market for CRISPR Technology, 2019-2027
Figure 35: Asia-Pacific Market Shares of CRISPR Technology, by Country, 2021
Figure 36: Chinese Market for CRISPR Technology, 2019-2027
Figure 37: Japanese Market for CRISPR Technology, 2019-2027
Figure 38: Indian Market for CRISPR Technology, 2019-2027
Figure 39: Rest of Asia-Pacific Market for CRISPR Technology, 2019-2027
Figure 40: RoW Market for CRISPR Technology, 2019-2027
Figure 41: Caribou Biosciences: Annual Revenue, 2019-2021
Figure 42: CRISPR Therapeutics AG: Annual Revenue, 2019-2021
Figure 43: Danaher: Annual Revenue, 2019-2021
Figure 44: Danaher: Market Share, by Region, 2021
Figure 45: Danaher: Market Share, by Business Segment, 2021
Figure 46: Editas Medicine: Annual Revenue, 2019-2021
Figure 47: GenScript: Annual Revenue, 2019-2021
Figure 48: GenScript: Market Share, by Business Segment, 2021
Figure 49: GenScript: Market Share, by Region, 2021
Figure 50: Intellia Therapeutics Inc.: Annual Revenue, 2020 and 2021
Figure 51: Lonza Group Ltd.: Annual Revenue, 2019-2021
Figure 52: Lonza Group Ltd.: Market Share, by Region, 2021
Figure 53: Lonza Group Ltd.: Market Share, by Business Segment, 2021
Figure 54: PerkinElmer: Discovery and Analytical Solutions, Revenue, 2019-2021
Figure 55: PerkinElmer: Market Share, by Business Segment, 2021
Figure 56: PerkinElmer: Market Share, Discovery and Analytical Solutions, by Region, 2021
Figure 57: Precision BioSciences: Annual Revenue, 2019-2021
Figure 58: Precision BioSciences: Market Share, by Business Segment, 2021
Figure 59: Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021
Figure 60: Thermo Fisher Scientific Inc.: Market Share, by Region, 2021
Figure 61: Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2021

Samples

Loading
LOADING...

Executive Summary

Reasons for Doing This Study:

  • CRISPR offers lucrative potential for advanced pharmacological research, with impact spanning the entire preclinical drug discovery pipeline. This technology makes gene editing more tractable and precise and speeds up the process of identifying drug targets and generating realistic disease models. High costs associated with the innovation of new drugs are a risk for pharmaceutical companies and may limit the discovery of new therapeutics. New and advanced technologies like CRISPR remove these barriers, expanding the drug exploration process.
  • This report examines end users, applications, and markets in an effort to help companies and investors prioritize product opportunities and strategic movements. The report highlights key industry and market trends and quantifies the main market segments, allowing the reader to better understand the industry’s structure and the changes occurring within it.
  • Favourable government regulations and funding that supports the application of CRISPR in various scientific fields across all regions create unique market opportunities. This report analyzes the trends and the impact on future growth and developmental opportunities of CRISPR applications in science.

Companies Mentioned

  • Caribou Biosciences
  • Crispr Therapeutics AG
  • Danaher Corp.
  • Editas Medicine
  • Genscript
  • Hera Biolabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences Inc.
  • New England Biolabs Inc.
  • Origene Technologies
  • Perkinelmer
  • Precision Biosciences
  • Synthego
  • Thermo Fisher Scientific
  • Toolgen Inc.

Table Information